Study of Prevalence of Raynaud’s Phenomenon in Porto
DOI:
https://doi.org/10.24950/rspmi/original/185/4/2018Keywords:
Portugal, Prevalence; , Raynaud Disease/complications, Raynaud Disease/diagnosis, Raynaud Disease/ epidemiologyAbstract
Introduction: Raynaud’s phenomenon (RP) is characterized by a color changed on the skin and extremities triggered by cold exposure and emotional stress. Its prevalence in Portugal is unknown.
Material and Methods: A cross sectional study was carried out in the region of Grande Porto, Portugal. The non-random sample was composed of 663 subjects, of both genders, varying from 15 to 64 years old. The association between RP’s prevalence and age, gender, marital status, county of residence, profession, occupational exposure to chemical products, vibratory tools and refrigeration systems was investigated. Participants were classified as having RP based on UK Scleroderma Study Group criteria (“A” criteria) and Maricq’s scale of distal finger color (“A+B” criteria). Data were analyzed using the chi-square and McNemar tests. Statistical significance was set at p < 0.05.
Results: Applying “A” criteria, the prevalence of RP was 4.5% (5.6% in women versus 2.3% in men) and with “A+B” criteria the prevalence of RP was 1.7% (2.0% in women versus 0.9% in men). Only occupational exposure to chemical products was significantly and positively associated with RP. Pallor fingers were the most reliable symptom of RP, regardless the criteria used.
Conclusion: Depending on the criteria, the prevalence of RP in Grande Porto varied between 1.7% and 4.5%, and these findings were similar to those found in some other countries. In contrast with other studies, age, gender, occupational exposure to vibratory tools and refrigeration systems had no association to RP
Downloads
References
Gayraud M. Raynaud´s phenomenon. Joint Bone Spine. 2007;74:e1-e8.
Handa R, Kumar U, Pandey RM, Aggarwal P, Biswas A, Wali JP. Raynaud’s phenomenon – a prospective study. JIACM. 2002;3:35-8.
Reilly A, Snyder B. Raynaud Phenomenon. Am J Nurs. 2005;105:56-65.
Bowling JC, Dowd PM. Raynaud´s disease. Lancet. 2003;361:2078-80.
Sunderkötter C, Riemekasten G. Pathophysiology and clinical consequences of Raynaud´s phenomenon related to systemic sclerosis. Rheumatology. 2006;45Suppl 3:iii33-iii5.
Cooke JP, Marshall JM. Mechanisms of Raynaud’s disease. Vasc Med. 2005;10:293-307.
Belch J. Raynaud’s phenomenon. Cardiovasc Res. 1997;33:25-30.
Nagata C, Yoshida H, Mirbod SM, Komura Y, Fujita S, Inaba R, et al. Cutaneous signs (Raynaud’s phenomenon, sclerodactylia, and edema of the hands) and hand-arm vibration exposure. Int Arch Occup Environ Health. 1993;64:587-91.
Block JA, Sequeira W. Raynaud´s phenomenon. Lancet. 2001;357:2042-8.
Ho M, Belch JJ. Raynaud´s phenomenon: state of the art 1998. Scand J Rheumatol. 1998;27:319-22.
Grassi W, De Angelis R, Lapadula G, Leardini G, Scarpa R. Clinical diagnosis found in patients with Raynaud’s phenomenon: a multicentre study. Rheumatol Int. 1998;18:17-20.
Ziegler S, Brunner M, Eigenbauer E, Minar E. Long-term outcome of primary Raynaud´s phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. Scand J Rheumatol. 2003;32:343-7.
Suter LG, Murabito JM, Felson DT, Fraenkel. The incidence and natural history of Raynaud’s phenomenon in the community. Arthritis Rheum. 2005;52:1259-63. doi: 10.1002/art.20988.
Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M. Transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon identified by diagnosis of an associated disease. Arthritis Rheum. 2006;54:1974-81. doi: 10.1002/art.21912.
De Angelis R, Del Medico P, Blasetti P, Cervini C. Raynaud’s phenomenon: clinical spectrum of 118 patients. Clin Rheumatol. 2003;22:279-84.
Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta- -analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med. 1998;158:595-600.
Matucci-Cerinic M, Allanore Y, Czirják L, Tyndall A, Müller-Ladner U, Denton C, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis. 2009;68:1377-80. doi: 10.1136/ard.2008.106302.
De Angelis R, Salaffi F, Grassi W. Raynaud´s phenomenon: prevalence in an Italian population sample. Clin Rheumatol. 2006;25:506-10. doi: 10.1007/ s10067-005-0077-1.
Leppert J, Aberg H, Ringqvist I, Sörensson S. Raynaud´s phenomenon in a female population: prevalence and association with other conditions. Angiology. 1987;38:871-7.
Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud´s phenomenon in general practice. BMJ. 1990;301:590-2.
Voulgari PV, Alamanos Y, Papazisi D, Christou K, Papanikolaou C, Drosos AA. Prevalence of Raynaud´s phenomenon in a healthy Greek population. Ann Rheum Dis. 2000;59:206-210.
Onbaşi K, Sahin I, Onbaşi O, Ustün Y, Koca D. Raynaud´s phenomenon in a healthy Turkish population. Clin Rheumatol. 2005;24:365-9. doi: 10.1007/ s10067-004-1045-x.
Çakir N, Pamuk ON, Dönmez S, Barutçu A, Diril H, Odabaş E, Kiliçcigil V. Prevalence of Raynaud´s phenomenon in healthy Turkish medical students and hospital personnel. Rheumatol Int. 2008;29:185-8. doi: 10.1007/s00296- 008-0666-9.
Purdie G, Harrison A, Purdie D. Prevalence of Raynaud’s phenomenon in the adult New Zealand population. N Z Med J. 2009;122:55-62.
Maricq HR, Weinrich M. Diagnosis of Raynaud’s phenomenon assisted by color charts. J Rheumatol. 1988;15:454-9.
Fraenkel L. Raynaud´s phenomenon: epidemiology and risk factors. Curr Rheumatol Rep. 2002;4:123-8.
Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F, et al. Different factors influencing the expression of Raynaud´s phenomenon in men and women. Arthritis Rheum. 1999;42:306-10.
Freedman RR, Mayes MD. Family aggregation of primary Raynaud’s disease. Arthritis Rheum.1996;39:1189-91.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
